TLCM
ALLO icon

Twin Lakes Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Twin Lakes Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81K Sell
740
-1,217
-62% -$2.44K ﹤0.01% 207
2025
Q4 		$2.68K Hold
1,957
– – ﹤0.01% 210
2025
Q3 		$2.43K Hold
1,957
– – ﹤0.01% 211
2025
Q2 		$2.21K Hold
1,957
– – ﹤0.01% 212
2025
Q1 		$2.86K Hold
1,957
– – ﹤0.01% 208
2024
Q4 		$4.17K Hold
1,957
– – ﹤0.01% 216
2024
Q3 		$5.48K Hold
1,957
– – ﹤0.01% 214
2024
Q2 		$4.56K Hold
1,957
– – ﹤0.01% 222
2024
Q1 		$8.75K Hold
1,957
– – 0.01% 210
2023
Q4 		$6.28K Hold
1,957
– – ﹤0.01% 218
2023
Q3 		$6.2K Hold
1,957
– – ﹤0.01% 225
2023
Q2 		$9.73K Hold
1,957
– – 0.01% 207
2023
Q1 		$9.67K Hold
1,957
– – 0.01% 205
2022
Q4 		$12.3K Sell
1,957
-1,020
-34% -$9.44K 0.01% 198
2022
Q3 		$32K Hold
2,977
– – 0.03% 158
2022
Q2 		$34K Hold
2,977
– – 0.02% 115
2022
Q1 		$27K Buy
2,977
+208
+8% +$2.17K 0.02% 179
2021
Q4 		$41K Sell
2,769
-203
-7% -$3.58K 0.02% 171
2021
Q3 		$76K Sell
2,972
-565
-16% -$13.4K 0.04% 125
2021
Q2 		$92K Sell
3,537
-756
-18% -$21.6K 0.05% 106
2021
Q1 		$152K Buy
+4,293
New +$145K 0.09% 90

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Lakes Capital Management's ALLO Position: Q1 2026 in Review

Twin Lakes Capital Management reduced its Allogene Therapeutics (ALLO) stake by 62% in Q1 2026, selling an estimated $2.44K and leaving 740 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #207.

Twin Lakes Capital Management first reported a position in ALLO in Q1 2021 and has held it in 21 quarters since. The position peaked at $152K in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Twin Lakes Capital Management held 740 shares of Allogene Therapeutics worth $1.81K as of Q1 2026.
  • Twin Lakes Capital Management sold 1,217 Allogene Therapeutics shares in Q1 2026, an estimated $2.44K.
  • Allogene Therapeutics made up ﹤0.01% of Twin Lakes Capital Management's portfolio in Q1 2026, its #207 holding.
  • Twin Lakes Capital Management first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Twin Lakes Capital Management's Allogene Therapeutics position peaked at $152K in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.